Comparing IDegLira and insulin glargine in short-term intensive treatment for overweight or obese type 2 diabetes patients

Insulin degludec/liraglutide (IDegLira) was compared to insulin glargine for glycemic control in overweight or obese patients with type 2 diabetes mellitus.

• IDegLira may improve short-term blood sugar control compared to insulin glargine.
• Both treatment options were used alongside insulin aspart.
• The study focused on patients with overweight or obesity and type 2 diabetes.
• Efficacy was assessed in the context of intensive glycemic management.

Simplified